Drug Approval | October 19, 2021
MSN Labs launches drug for diabetes management
The company claims that its Empagliflozin tablets are the most affordable in India
The company claims that its Empagliflozin tablets are the most affordable in India
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
The company plans to expand its portfolio in regulated markets aggressively
Droxidopa capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The consultations are virtual and they have launched the Diabetes Reversal Programme to address the issue
Between 30-40 per cent of Covid-19 patients are either obese or diabetic
The company plans to enter the formulation business in January 2022. It has also opened a branch in Hyderabad to trade pharmaceutical chemicals
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Subscribe To Our Newsletter & Stay Updated
